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Ribosome biosynthesis in eukaryotes is a 
highly coordinated process requiring a con-
certed activity of three nuclear RNA poly-
merases (RNA Pol i–iii). in yeast RNA synthesis 
by Pol i and Pol iii represents more than 80% of 
all nuclear transcription.1 RNA Pol i is dedicated 
to the synthesis of 35S pre-rRNA which is sub-
sequently processed to ribosomal 25S, 18S and 
5.8S rRNA. tRNAs, 5S rRNA and several other 
small noncoding RNAs are synthesized by Pol iii. 
Because of the high energy cost of Pol i and Pol 
iii activity, coordination of their activities with 
environmental growth conditions provides a 
powerful selective advantage. Much of this regu-
lation is achieved by the TORC1 complex with 
the evolutionarily conserved TOR kinase as the 
catalytic subunit. TORC1 activity is inhibited by 
the macrolide drug rapamycin which binds to 
the complex and suppresses its interaction with 
target substrates. yeast TORC1 shuttles dynami-
cally between the cytoplasm and nucleus and 
when present in the nucleolus, it binds to rDNA 
chromatin, 35S as well as 5S genes.2 Significantly, 
although TORC1 does not bind to tRNA genes, 
it modulates tRNA transcription indirectly by 
phosphorylation of a Pol iii repressor, Maf1.2 
Maf1, first identified in yeast 3, is an evolu-
tionarily conserved general negative regulator 
of Pol iii. Upon rapamycin treatment, Maf1 is 
imported to the nucleus,4,5 and is detectable in 
the nucleolus.2 TORC1 interacts with Maf1 and 
phosphorylates Maf1 at the rDNA loci, in this 
way regulating its translocation from the nucle-
olus to the nucleoplasm.2 However, yeast Maf1 
contains nearly 30 potential phosphorylation 
sites specific for several different kinases beside 
TOR (data according to Swiss-Prot PROSiTe). 
Moreover, phosphorylation was recognized ear-
lier as the main way of inactivating Maf1 in 
favorable growth conditions, by preventing its 
interaction with Pol iii.4,5 Additionally, phospho-
rylation acts both to relocate the nuclear pool 
of Maf1 to the cytoplasm6 and to prevent the 
import of cytoplasmic Maf1 to the nucleus.7 The 
paper by Wei and Zheng, published in this issue 
of Cell Cycle describes Sch9 as a Maf1 kinase and 
proposes a mechanism by which TORC1 and 
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Sch9 jointly control Pol i and Pol iii in yeast8 
(Figure 1).
Sch9 is a member of the AGC kinase family 
that mediates TORC1 regulation of ribosomal 
protein genes transcription by Pol ii.9 yeast 
Sch9 is phosphorylated at multiple sites by 
TORC1, which is required for Sch9 catalytic 
activity.9 Replacing these residues with acidic 
amino acids yields a protein variant termed 
Sch9(2De), which is active even in the absence 
of an upstream signal from TORC1. Since Pols 
are co-regulated by TORC1, it is not surpris-
ing that also Sch9 is involved in Pol i and Pol 
iii control. This is likely to constitute a highly 
efficient mechanism for coordination of protein 
biosynthesis. Maf1, identified by Wei and Zheng 
as an Sch9 target, functions in this mechanism as 
a mediator of the nutrient signal to Pol iii.8 Sch9 
interacts with Maf1 and phosphorylates Maf1 in 
a rapamycin-dependent manner. Moreover, in 
the Sch9(2De) mutant Maf1 phosphorylation is 
independent of rapamycin treatment, confirming 
that Sch9 mediates TORC1 signaling. Altogether, 
the data of Zheng’s group show that TORC1 
controls Maf1 not only indirectly in the nucleo-
lus but also directly, via Sch9 in the nucleoplasm. 
To pinpoint the role of Sch9 in this regulation, 
Wei and Zheng showed that combined muta-
tions inactivating Sch9-dependent phosphoryla-
tion sites on Maf1 are sufficient to cause Maf1 
entry to the nucleus, essentially the same phe-
notype as that caused by Sch9 inactivation. Sch9 
affects Pol iii activity in an obvious way: tRNA 
synthesis was increased in the hyperactive 
mutant Sch9(2De) and markedly decreased in a 
strain lacking Sch9. importantly, the basal Pol iii 
transcription that occurs in the absence of Sch9 
was still sensitive to rapamycin, thus validating 
the previously described Sch9- independent 
effect of TORC1 on Pol iii activity.2,10
The point of TORC1-mediated Pol iii con-
trol is the regulation of nuclear-nucleolar Maf1 
dynamics. Nucleolar localization of Maf1, crucial 
for Maf1 activation, is not affected by Sch9 
restricting this control to TORC1 itself. is then 
the role of Sch9 phosphorylation of Maf1 lim-
ited to promoting its cytoplasmic location? This 
seems to be an underestimation since cytoplas-
mic-nuclear transport of Maf1 is known to be 
dispensable for Pol iii regulation.6,7 Moreover, 
a recent report by Huber et al. (2009) shows 
that besides affecting its nuclear transport, Maf1 
phosphorylation by Sch9 regulates its interac-
tion with Pol iii.11 Mutations of Maf1 that mimic 
phosphorylation by Sch9 prevent its association 
with Pol iii while inactivation of all Sch9 target 
sites in Maf1 promotes Maf1-Pol iii association. 
How it happens, assuming the effect of Sch9 
on Maf1 is restricted to nucleoplasm and Maf1 
final destination is the nucleolus, remains to be 
elucidated. Nevertheless, inactivation of Sch9 
does not promote interaction of Maf1 with Pol 
iii.11 Additionally, neither Maf1 mutants prevent-
ing nor these mimicking Maf1 phosphorylation 
by Sch9 did not affect the rapamycin–mediated 
repression of Pol iii,11 providing a final argument 
for the conclusion of Wei and Zheng that phos-
phorylation of Maf1 by Sch9 is not crucial for 
Pol iii regulation in response to nutrient. 
The balanced production of 5S and 35S 
rRNA requires coordinated regulation of Pol iii 
and Pol i. TORC1 was proposed to control Pol 
i via recruitment of the essential Rrn3 initiation 
factor.12 Sch9 is also involved in rapamycin-sensi-
tive regulation of Pol i transcription,8,11 although 
the mechanism is unknown. Obviously, multiple 
levels of control are involved in the balancing of 
the numerous ribosomal components. 
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Figure 1. Sch9 partially mediates TORC1 signaling to activate Pol i and Pol iii transcription by nutrients. in the presence of nutrients TORC1 pro-
motes Pol i and Pol iii transcription in the nucleolus and phosphorylates Maf1 preventing its negative effect on Pol iii. Additionally, TORC1 activates 
Sch9 and uses Sch9 to phosphorylate Maf1 in the nucleus and promote its export to the cytoplasm. Bold lines, activation/repression; empty lines, 
changes in localization).
When cells are exposed to proteotoxic 
stress, they depend on the activation of several 
cytoprotective cellular response mechanisms 
for survival. To protect against this stress, cells 
induce the heat shock response (HSR), an 
ancient and highly conserved genome wide 
transcriptional program, by triggering the activa-
tion of heat shock factor 1 (HSF1), the master 
transcription factor that regulates inducible 
heat shock gene expression and the synthesis of 
additional chaperones. HSF1 coordinates induc-
tion of the HSR to refold and repair damaged 
proteins, preserve protein function and metabo-
lism, in order to restore cellular homeostasis 
and maintain cell survival under stress.1
Since cancer cells undergo extreme pro-
teotoxic stress, upregulation of the heat-shock 
response is essential to alleviate the negative 
effects of increased protein misfolding and turn-
over, competition among proteins for access to 
chaperones, and proteasomal stress. As such, 
tumors exhibit elevated levels of several heat 
shock proteins (HSPs), including HSP90,2 sug-
gesting that HSP overexpression may con-
tribute to aberrant tumor survival. Therefore, 
HSF1 is not only constitutively active but also 
orchestrates a broad network of key cellular 
processes that includes protein synthesis, glu-
cose metabolism, cell proliferation and survival, 
to enhance oncogenic transformation. indeed, 
HSF1 has been shown to be a potent modifier 
of tumorigenesis, facilitating in the initiation and 
maintenance of various cancers.3 Although HSF1 
is neither a classical oncogene nor tumor sup-
pressor, cancer cells can become dependent on 
HSF1 to modulate an entire network of cellular 
functions that enable tumorigenesis referred to 
as “non-oncogene addiction.”4 While oncogenes 
make attractive targets for the development of 
cancer therapeutics (e.g., tyrosine kinase inhibi-
tor imatinib), recent drug development efforts 
have been devoted to the growing list of non-
oncogenes (e.g., proteasome inhibitor bort-
ezomib) that may also be exploited as potential 
cancer drug targets and such is the case for the 
discovery of HSF1 inhibitors.5
in Cell Cycle volume 8, issue 23, Neznanov 
and colleagues show that the anti-malarial 
drug quinacrine can suppress HSF1-mediated 
heat shock response induced either by the 
proteasome inhibitor MG132, hsp90 inhibi-
tor 17-DMAG, or hyperthermia. The reduced 
HSF1-dependent transcription occurs at a 
point downstream of its cytoplasmic activa-
tion, nuclear translocation, and DNA binding, 
suggesting that quinacrine uses a mechanism to 
block transcription initiation that requires its 
own nuclear localization, similar to its inhibi-
tory effect on NF-kB-mediated transcription.6 
Moreover, the effects of quinacrine on inducible 
transcription appear selective since the drug 
stimulates p53-mediated transcription6 and can 
inhibit the prosurvival AKT/mammalian target 
of rapamycin (mTOR) pathway that lies down-
stream of Pi3K.7 The functional interplay among 
the Pi3K/AKT/mTOR, p53, NF-kB and now HSR 
pathways make quinacrine an even more attrac-
tive anticancer drug candidate since it appears 
to simultaneously and selectively target these 
multiple pathways.
The remarkable finding in the study lies in 
the combination treatment of quinacrine with 
proteotoxic stress inducers (e.g., proteasome 
and HSP90 inhibitors). Because targeting HSP90 
using inhibitors such as 17-DMAG has shown 
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limited therapeutic success in the past, the addi-
tion of quinacrine in this study actually enhances 
the cytotoxicity of 17-DMAG, augmenting 
both drugs’ efficacy. While the mechanism of 
enhanced cytotoxicity remains to be elucidated, 
a recent study shows that p53 functional status 
is a likely predictor of the sensitivity of tumors 
to 17-DMAG and that the administration of 
17-DMAG both retards tumor growth and 
engages p53-dependent cell death in vivo in 
murine medulloblastoma.8 it will therefore be 
interesting to determine the degree to which 
quinacrine can further enhance the cytotoxicity 
of 17-DMAG in this cancer model since qui-
nacrine also stimulates the p53 pathway and is 
known to cross the blood-brain barrier.
Taken together, these studies demonstrate 
that targeting the heat shock response, specifi-
cally HSF1, may facilitate the use of proteasome 
and HSP90 inhibitors for cancer treatment and 
opens up a unique avenue to explore potential 
treatment strategies involving these two classes 
of inhibitors within the HSR pathway. in fact, 
a screen of 20,000 small molecules for com-
pounds that inhibit HSP induction identified two 
analogs of the general translational inhibitor 
dehydroemetine that can sensitize cancer cells 
to the effects of proteasome and HSP90 inbii-
tors.9 Most recently, using a high-content target-
based screening assay for identifying small 
molecule functional inhibitors of HSF1, Au et al. 
has discovered a compound that inhibits HSF1 
granule formation and inhibits HSF1 phospho-
rylation.10 Whether investigators are involved in 
the discovery of novel selective HSF1 inhibitors 
or uncovering a previously unknown HSF1-
mediated mechanism of action of an existing 
drug, future studies are warranted in pre-clinical 
evaluation of their anticancer activity and poten-
tial therapeutic combinations with other classes 
of drugs (e.g., kinase inhibitors). 
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Breaks in DNA are caused by exogenous 
sources such as ionizing radiation (iR), radiomi-
metic drugs and by endogenous sources such 
as free radicals or replication fork collapse at 
single-strand lesions during S phase.1 Double 
Strand Breaks (DSBs) are amongst the most 
serious DNA lesions because they are difficult 
to repair, due to the lack of an undamaged 
complementary strand. Such breaks are usually 
repaired through homologous recombination 
(HR) and non-homologous end-joining (NHeJ). 
HR takes place in the late S-G2 phases, when 
DNA is replicated, while NHeJ happens mostly 
in the G1 phase of the cell cycle.1 The activa-
tion of the DNA damage response leads to 
cell cycle arrest until repair has taken place. 
The players of the DNA damage response are 
the components of the early DNA damage 
sensor complex MRN (MRe11/Rad50/NBS1), 
the transducer proteins MDC1 and 53BP1, the 
Pi3 kinases ATM/DNAPK/ATR, which phos-
phorylate the histone variant H2AX, and the 
downstream effectors including the Chk1 and 
Chk2 cell cycle kinases1 Unsuccessful DNA 
repair and accumulation of DNA damage can 
lead to mutations and chromosomal abnor-
malities, which are hallmarks of cancer.1 DNA 
repair pathways also have other essential roles 
in longevity since insufficient repair mecha-
nisms can lead to senescence, as shown by 
studies performed on mice defective for DDR 
proteins2
 Until very recently, the DNA damage 
response has been strictly associated with the 
induction of breaks to the DNA. This dogma 
has been lately challenged by several obser-
vations in mammalian and yeast cells. in this 
issue of Cell Cycle, Pospelova and colleagues 
report an additional case of a “pseudo DNA 
damage response,” which is manifested during 
senescence. They show that upon induction of 
senescence by activating p21 or p16, specific 
DDR markers are activated in the absence of 
detectable DNA breaks. More specifically, they 
observe robust formation of g-H2AX foci and 
uniform nuclear signal of phosphorylated ATM. 
Nevertheless, the observed DDR has several 
differences with the classical DDR activated by 
DNA damage. First, not all of the key players of 
the DDR appear to be implicated in this new 
pathway. While g-H2AX foci are formed, 53BP1 
foci are totally absent and phosphorylated ATM 
has a uniform nuclear staining that doesn’t 
colocalize with the g-H2AX foci. Second, the 
temporal kinetics of this DDR is slower than 
the one activated by DNA lesions. 
There is increasing evidence that DDR can 
be mounted in the absence of DNA lesions.1 
immobilization of repair proteins on chroma-
tin to mimic foci formation both in yeast and 
mammalian cells was shown to be sufficient to 
activate markers of DDR.3,4 Moreover, consti-
tutive activation of ATR by overexpression of 
small domain of the ATR-stimulating TopBP1 
protein leads to DNA damage-independent 
activation of DDR and subsequent cell cycle 
arrest and senescence.5 Moreover, g-H2AX is 
activated during mitosis where chromosomes 
are condensed.6 interestingly, the g-H2AX signal 
in mitotic chromosomes is devoid of 53BP1. 
This observation is in line with the pseudo 
DDR activation shown by Pospelova et al after 
treatment with the histone deacetylase (HDAC) 
inhibitor Nabutyrate to induce senescence, 
as well as the observed lack of colocalization 
between g-H2AX and 53BP1 in early mouse 
embryo in the absence of DNA damage.7 These 
observations raise the possibility that the DDR 
machinery senses not lesions per se but also 
changes in chromatin structure. Consistent with 
this notion, ATM is activated in response to 
changes in chromatin structure upon exposure 
of cells to the HDAC inhibitor TSA.8 
Although a classical DDR has so far been 
proposed to induce senescence,9 Pospelova 
et al demonstrate for the first time a DD-like 
response that is the consequence, not the cause, 
of senescence and they suggest that pseudo 
DDR is acting as a mechanism of perpetuating 
the senescence phenotype and protecting cells 
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from reentering to the cell cycle, which can lead 
to cellular abnormalities. 
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The proper storage and transfer of biologi-
cal information is of paramount importance to 
all living cells, and requires the services of 
numerous quality control systems to ensure 
operational fidelity.1 Because these systems 
constitute a series of cellular “checkpoints,” 
many have begun to question whether (and 
how) they might be coordinately regulated. This 
question is of particular interest to cancer cell 
biologists because numerous quality control 
systems are compromised during the process of 
carcinogenesis. in fact, the meaningful discovery 
of biomarkers to used as reliable diagnostic 
tools or prognostic indicators might depend 
on our ability to ultimately decipher how these 
interconnections are regulated, rather than to 
merely monitor changes in the intracellular 
concentrations of individual quality control 
components. 
in a forthcoming issue of Cell Cycle (volume 
9, issue 1), Chang and colleagues continue their 
use of fission yeast to reveal that a protein com-
plex known to facilitate the proper segregation 
of chromosomes during mitosis plays an addi-
tional role in regulating the quality of proteins 
that traverse the early secretory pathway. The 
authors had already identified the participation 
of these proteins in the proteasomal destruc-
tion of nucleo-cytoplasmic proteins (involved in 
chromosome segregation), as well as part of a 
supercomplex that recruits proteasomes to the 
translation machinery as a means to cotrans-
lationally degrade proteins unable to attain 
conformational maturation.2 The importance of 
the new study stems from their ability to begin 
to define the physical connections that establish 
this additional link to protein quality control 
in the secretory pathway where the events of 
translation and quality control are often tempo-
rally and spatially separated.
 As a rule, proteins unable to correctly fold 
in the endoplasmic reticulum (the first compart-
ment of the secretory pathway) are selectively 
dislocated back into the cytosol in response to 
the covalent addition of ubiquitin which also 
promotes proteasomal degradation.3 The entire 
process, consisting of sequential substrate selec-
tion and dislocation events has been designated 
‘endoplasmic associated degradation’ (eRAD).3 
Cdc48, the yeast homolog of mammalian p97, is 
known to transfer escort ubiquitinated eRAD 
substrates to proteasomes at the eR mem-
brane.4 The present study shows that Cdc48’s 
contribution is made possible through its physi-
cal interaction with Moe1 which is itself bound 
to yin6, the latter of which is directly bound 
to proteasomes. importantly, Moe1 and yin6 
are the fission yeast orthologs of two impor-
tant eukaryote translation initiation factor 3 
subunits, demonstrating the functional link to 
protein translation. Genetic deletion of the 
complex is not lethal, implying that it is not 
absolutely required and therefore either func-
tions to enhance the global efficiency of eRAD 
or is responsible for the eliminating only a sub-
set of eR-derived proteins. 
These multiple capacities might stem from 
the abilities of Cdc48 and the yin6-Moe1 com-
plex to individually influence additional pro-
cesses in the cell, including membrane fusion 
and intracellular protein transport. As such, the 
coordinate regulation might involve the dynamic 
assembly of an even larger molecular machine 
that is shuttled to distinct parts of the cell 
either in response to covalent modifications or 
through the utilization of interchangeable adap-
tors. in fact, this notion is in agreement with 
the fact that none of these proteins are known 
to directly interact with biological membranes. 
Additional studies are required to determine 
whether a “scaffold-dependent shuttling” model 
operates in fission yeast or in mammalian cells.
importantly, the altered expression of 
these proteins is often associated with cancer. 
Therefore, its role in chromosome segregation 
could account for the aneuploid phenotype 
often associated with cancer. in addition, a pro-
longed eR stress response that involves eRAD5 
is known to induce apoptosis.6 Therefore, a 
diminished concentration of the protein might 
actually prevent apoptotic cell death, provid-
ing cancerous cells with a competitive growth 
advantage. in fact, the idea fits well with the 
evolving paradigm that cancer progression 
results from the mis-regulation of numerous 
mechanisms, including an imbalance in the levels 
of pro-apoptotic and anti-apoptotic factors.
Finally, it is not surprising that cellular func-
tions might be under the control of dynamic 
molecular machines that consist of interchange-
able parts (Figure 1). This arrangement would 
allow for the coordinate linkage of checkpoints 
that must operate throughout living cells. The 
acquired knowledge generated from this, and 
additional, studies should help to illuminate 
the fundamental mechanisms by which this 
series of critical checkpoints are functionally 
linked, and eventually demonstrate whether any 
apparent mis-regulation associated with cancer 
is amenable to mechanism-based therapeutic 
intervention. 
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Regenerative medicine is the replacement 
of damaged or diseased cells with new healthy 
functional cells, usually from an exogenouse 
source. Although embryonic stem cells play a 
central role in cell based therapy research the 
best example is the use of hematopoietic stem 
cells for bone marrow transplant to treat blood 
malignancies.1
Decades of research have produced prom-
ises and revealed pitfalls of cell based therapy.2 
There are a number of hurdles that need to 
be addressed in order for stem cells to be 
considered for therapeutic use, such as safety, 
sufficient cell numbers, accessibility, availability 
when required, efficient mode of delivery to the 
target organs, high engraftment and differen-
tiation rate and a functional improvement after 
transplantation. Some laboratories have chosen 
to address these hurdles by taking advantage 
of endogenous stem cells instead of using an 
exogenous cell source. By inducing the patient’s 
own cells, in situ, to act as a replacement cell 
source, the problems of tissue matching, avail-
ability and delivery are eliminated leaving only 
the issue concerning efficiency of differentiation 
and return of tissue function. An example of this 
has been demonstrated by the stimulation of 
endogenous cells in spinal cord injury models.3 
However the use of endogenous stem cells 
also has its limitations. The tissue damage could 
be so extensive that the endogenous stem 
cells or the cell niche could be damaged or 
even absent. For example, in the case of type 2 
diabetes there is evidence that the endogenous 
endothelial progenitor cells are damaged and 
incapable of repairing damaged blood vessels.4 
To circumvent this problem, in the cases similar 
to the situation found with diabetes, we can 
come full circle and suggest the use of exog-
enous stem cells or use a novel approach which 
is to take advantage of trans-differentiation 
and induce unrelated cells in the vicinity of 
the injured area to contribute to tissue repair.5 
Although trans-differentiation is a poorly under-
stood process the ability of the mature cells 
to give rise to cells of a different type has 
been well documented. The ability of cells to 
trans-differentiate has been demonstrated in 
multiple systems although whether the event is 
due to trans-differentiation6 or reprogramming 
to an early embryonic state followed by redif-
ferentiation to a new mature cell type, remains 
unclear.7,8
Historically, the ability of cells to transdif-
ferentiate or to be reprogrammed went against 
embryo and developmental biology paradigms 
that described development as a stage specific, 
linear progression which lead to a terminally 
differentiated state. Regeneration in amphib-
ians and wound healing in mammals suggested 
that there were exceptions to the rule. in the 
last decade there have been multiple reports 
suggesting trans-differentiation of mature cell 
types9 but in some cases these reports were 
also challenged.10 After almost a decade of con-
troversy it was reported that the introduction 
of just four genes were capable of converting a 
skin fibroblast to a cell identical to pluripotent 
embryonic stem cells.8 This work and subse-
quent publications clearly demonstrate the 
plasticity of cells, opening the door to studies 
such as the one described here.
Dr. Bukovsky previously demonstrated that 
a combination of sex steroids such as estradial, 
testosterone and progesterone have the ability 
to trans-differentiate ovarian epithelial cells to 
neural stem cells.11 in their recent publication 
they have demonstrated that smooth muscle 
cells in the vasculature can also be induced to 
trans-differentiate into neural cells using the 
same combination of sex steroids (Bukovsky, 
this journal). Sex steroids are not normally used 
to induce the differentiation of stem cells or 
the trans-differentiation of mature cells as the 
majority of reports have used transgenes or 
growth factors. Although neural cells appeared 
infrequently in the cultures their appearance 
increased if the cells were exposed to combi-
nations of estradial, progesterone and testos-
terone, however, individually these factors are 
ineffective. Current methods using transgenes, 
recombinant growth factors or chemicals to 
induce endogenous cells to repair damaged 
Figure 1. A protein complex can apparently 
regulate mitotic spindle formation, protein 
translation, and proteasomal degradation, 
possibly by employing interchangeable parts 
and/or through a scaffold-dependent shuttling 
mechanism.  Moe1 and Yin6 are the fission 
yeast homologs for the eukaryote translation 
initiation factors eiF3e and eiF3d, respec-
tively, that provides a molecular scaffold that 
allows Cdc48 to escort eRAD substrates for 
degradation by cytoplasmic proteasomes.
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tissue may not be suitable for the clinic but sex 
steroids are good candidates as their main advan-
tage is that they are normally present and are 
able to cross the blood-brain barrier leading to 
the stimulation of endogenous cells in the brain 
and spinal cord. Although stem cell based therapy 
holds much promise the issues of cell source, tis-
sue matching and cell delivery are major hurdles 
that need to be overcome. This can be solved by 
the stimulation of endogenous cells localized to 
the area of damage. Furthermore not having to 
use exogenous cells or transgenes will fast track 
this technology through clinical trials.12,13
The investigation of sex steroids as inducers 
of trans-differentiation of smooth muscle cells 
associated with the vasculature into neural cells 
is novel and introduces an alternative method 
of regenerative medicine. Smooth muscle cells 
are abundant throughout the vasculature and 
stimulation of these endogenous cells to pro-
duce neurons or neural stem cells in an area 
of neural damage could lead to repair and the 
return of function without the requirement for 
cell transplantation.
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